Recent studies reinforce that weight loss is not simply an esthetic consideration. It has very real benefits in terms of ...

This list can have an impact on your drug coverage in 2025 and shows why this open enrollment is so important.

The Danish drugmaker plans to introduce a combination drug, CagriSema, that could result in 25% weight loss — higher than ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.

Almost 16% of American adults — or about 1 in 6 — have type 1 or type 2 diabetes, the US Centers for Disease Control and ...

Wegovy and Ozempic drove Novo Nordisk to record bumper sales since ... Biocon (which already has large-scale peptide ...

President-elect Donald Trump has promised Kennedy a large role in the new administration and signaled he could be in charge ...

Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...